Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00578149 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00578149 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 45 participants.
The verdict
NCT00578149, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study is being done to learn what effects (good and bad) bevacizumab in conjunction with carboplatin/paclitaxel and radiation therapy has on patients with non-small cell lung cancer (NSCLC).
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00578149
The ClinicalTrials.gov registry entry for NCT00578149 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00578149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00578149 about?
NCT00578149 is a clinical study titled "Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer". This study is being done to learn what effects (good and bad) bevacizumab in conjunction with carboplatin/paclitaxel and radiation therapy has on patients with non-small cell lung cancer (NSCLC).
What is the current status of trial NCT00578149?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2006-05. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00578149?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00578149?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.